Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 8 of 8 entries
View as:

A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL

Phase: N/A Priority: Normal
NCT ID: NCT02323230 Org: User:
Start: 01/31/15 End: 02/28/18 Due: 02/28/19

Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03332576 Org: User:
Start: 08/23/13 End: 09/09/19 Due: 09/09/20

A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01095848 Org: User:
Start: 03/31/10 End: 11/30/11 Due: 11/30/12

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03836352 Org: User:
Start: 12/21/18 End: 12/31/23 Due: 12/31/24

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04920617 Org: User:
Start: 06/18/21 End: 04/30/25 Due: 04/30/26

Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05243524 Org: User:
Start: 08/05/22 End: 08/31/23 Due: 08/31/24

Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01416038 Org: User:
Start: 12/31/11 End: 05/31/13 Due: 05/31/14

Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02785250 Org: User:
Start: 04/30/16 End: 05/31/25 Due: 05/31/26